Lung Cancer: Advice That Helps, Advice That Hurts
A non-small-cell lung cancer survivor and advocate shares the words that helped and hurt her the most. (Source: WebMD Health)
Source: WebMD Health - November 15, 2022 Category: Consumer Health News Source Type: news
Drug Trials Snapshot: TEPMETKO
TEPMETKO is a drug used to treat adult patients with a type of non-small cell lung cancer (NSCLC) which has a specific set of gene alterations and has spread to other parts of the body (metastatic). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - November 14, 2022 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Imfinzi and Imjudo with Chemotherapy Approved in the US for Patients with Metastatic Non-Small Cell Lung Cancer
Approval based on POSEIDON Phase III trial results, which showed significant survival benefit with a limited course of Imjudo added to Imfinzi and chemotherapy
11 November 2022 -- AstraZeneca’s Imfinzi (durvalumab) in combination with... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 11, 2022 Category: Drugs & Pharmacology Source Type: news
EQRx No Longer Seeks To Disrupt Prices In Non-Small Cell Lung Cancer Space
The biotechnology company EQRx no longer seeks to disrupt prices in the non-small cell lung cancer space. This is disappointing news for those who had hoped for lower prices in a therapeutic category that, for the most part, has been sorely lacking real price competition for years. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - November 10, 2022 Category: Pharmaceuticals Authors: Joshua Cohen, Contributor Tags: Healthcare /healthcare Innovation /innovation business pharma & Source Type: news
FDA approves tremelimumab in combination with durvalumab and platinum-based chemotherapy for metastatic non-small cell lung cancer
On November 10, 2022, the Food and Drug Administration approved tremelimumab (Imjudo, AstraZeneca Pharmaceuticals) in combination with durvalumab (Imfinzi, AstraZeneca Pharmaceuticals) and platinum-based chemotherapy for adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensi (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - November 10, 2022 Category: Drugs & Pharmacology Authors: FDA Source Type: news
